Australian Cancer Trial Advances with First Cohort Complete, Amended Protocol, and Promising Preclinical Data Published; Operating Expenses Cut by 32% SAN DIEGO, Aug. 13, 2025 ( Investorideas.com Newswire)…
Tag:
AEMD
-
-
Investment
AEMD) Announces Financial Results for the Fiscal Third Quarter Ended December 31, 2024 and Provides Corporate Update
SAN DIEGO – February 12, 2025 (Investorideas.com Newswire) Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported…